A securities class action lawsuit has been filed against Organon & Co. on behalf of investors who purchased the company's securities between October 31, 2024, and April 30, 2025. The lawsuit claims that Organon, following its $1.2 billion acquisition of Dermavant, assured investors that maintaining its dividend was its top capital allocation priority. However, it is alleged that the company shifted its focus to debt reduction instead. Investors have until July 22, 2025, to seek appointment as lead plaintiff in the case. Organon, headquartered in Jersey City, NJ, specializes in women's health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.